ALLO - Earnings call transcript Q4 2019 | Allogene Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and thank you for standing by, and welcome to Allogene Therapeutics' Foruth Quarter 2019 Conference Call. [Operator Instructions] Please be aware, that today's conference is being recorded.

I would now like to turn the conference over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano

good and operator, you, morning. Thank

December today, Before our that fourth website a press ended releases, at www.allogene.com. issued a market quarter is corporate on full-year the opened provides for update press results The Allogene and available XXXX. XX, and release financial

We remind being call today's webcast and website our listeners available be that will for is on replay.

Research Chief Raphael are and Chief Joining Officer President Amado, Vice Eric me Financial Chang, Executive on Schmidt, and Dr. Officer. the David and President and Dr. of call Medical Officer; Dr. Development today Chief Executive

certain During the today's guidance among call capabilities forward-looking our trials, we statements. timing and things. and other future may will ongoing regarding manufacturing be development statements filings, XXXX planned and clinical making regulatory and include financial of and These success research efforts

differ other described statements that in Commission, forward-looking to subject risks and These assumptions as with information, Exchange upcoming well based cause and These in XX-Q current XXXX, and may for are our that XX-K actual year ended from XX, and are and number are expectations to the forward-looking involve materially of uncertainties those XXXX. filings statements. the XX, a contained change periodic on Form Form September Securities the including the for our made as December quarter our ended risks results

update statements. reliance forward-looking and statements such disclaims undue obligation these to on are place to not You cautioned the company any

over call the turn David now Dr. I'll Chang. to

David Chang

bringing of in capabilities management, have built We to extremely steady pleased the to morning and ahead. critical am the our progress what and to the California, making manufacturing New facility us facility we fourth the year online towards XXXX. Good cell join on our for you initiated GMP discuss accomplished call completed today in and close hiring thank time XXXX. of our functions taking I York, in world-class with senior build-out quarter

and clinical ALLO-XXX myeloma. programs, non-Hodgkin ALLO-XXX in initiated in lymphoma multiple relapsed/refractory we importantly, two Most relapsed/refractory

pace. Our the and anticipate ALLO-XXX we key momentum is still working XXXX, quarter in are advancing and continuing data the also we an we quarter. years. trials additional technologies initial reporting next early towards to clinical accelerated which we programs into plan created coming of team clinical and engineering two is but the year, research introduce It in generation this for cell programs, working fourth This at in year ALLO-XXX last second the year in

IND our expanding progress ALLO-XXX, to as clinical next our which on look-forward also CDXX. We candidate we portfolio targets

remain lifesaving and making, focused and All selectivity this will therapy platform next three; Number achieve to ALLO advancing reality CAR validate a to development and the leadership Allogene goal intends we CAR foundational platform out, through of ALLO to our number three The success laid for recently the T the ALLO part T therapy CAR and team employees to be strategy singularly our of establish potency XXX of two; enhance on cells. T clinical Allogene Number at technologies product one one; candidates, the ALLO strengthen multiple of generation by in that T in CAR future their transform our plus goal. potential position therapy. a patients. rapid

validation walk and you our of me concept through platform Let transformation.

A. to While manufactured that allow T phenomenon cell of one large there to use patients independent healthy type between a for key are needs similarities CAR immunological HLA allogeneic autologous are and number cells of there from of therapy, allogeneic donor unrestricted addressed be

the allogenic to therapy appropriate therapy the patients control success at cell T the graft Specifically, versus to are a address needs therapy conveniently inherent the early prevent shelf deliver ability and CAR faster of host to an to these the risk and issues, namely that more of disease cost therapy can graft ALLO reduced Once manufacturing. all of of benefits off be realized, one as rejection. key

creating an in from host T strategy. cells propriety ALLO T the limited ability technology [indiscernible] is mount talent data cells. the Early us novel the approach therapy of gene CAR manufacturing generated Cell receptor platform lympho from candidates novel by the allogeneic or based as receptor being efficiently out use Our cell our have cell TALEN editing to a processes and T cell as state-of-the-art depletion graft on edit response. in allow lacking versus to data now UCARTXX studies well manufacturing support to and others TALEN field,

graft and strategy to purpose that overcome chemotherapy of expansion has well from We controllable CAR lymphodepletion the others ALLO suited to use of use for ALLO-XXX requires of the persistence modified second enabling the of ALLO-XXX, the T upon based beyond a CAR be The our early is our period durable antibody believe to selected based our a have to T of challenge, ALLO resistant We lymphodepletion effect differentiates our and to lymphodepletion. and goes creating the rejection to lymphodepleting rejection which critical is strategy agents novel that and ALLO-XXX. T cells. of our anti-CDXX ability a prevent facilitate been and early selected ALLO CAR traditional of

the patients therapy. who of sufficient, as benefit, clinical anti-CDXX responsive will while ALLO-XXX depletion cyclophosphamide that both an chemotherapy cell evidence received fludarabine lymphodepletion experienced their studies. proof part low expansion comes studies for not for may who initial only based flu/cy used alone and UCARTXX of compelling These provided to received The not failed dose to demonstrate and anybody those majority of the regimen baseline high concept which from the and lymphodepletion be

they're optimal ALLO-XXX the unique T clinical control by depth and persistence length provides a lymphodepletion, us variety expansion to determine of a of all settings. selectively and us cell explore with window We CAR to ALLO allowing opportunity believe for in and the

chemotherapy, with agent, that. of effects to cytopenia us only the cells. of targeted CAR In impacting lymphodepleting from cells summary, we is the dosed, lymphodepletion platform durable clinical we we and validation a platform CDXX at associated that T only can obtain broader leads viability that believe ALLO have flexibly ALLO express inducing lymphodepletion not is be the of This our without because capable can hope trials. to no other it do ALLO-XXX

and data quarter that ALPHA ALLO ALLO-XXX present on We relapse/refractory the relapsed/refractory trial an to are CAR to these multiple-myeloma and year, from non-Hodgkin's are for T in assess initial quarter fourth cell trial ALLO-XXX track X appropriate lymphoma Phase in in the second designed dose. safety establish trials this

trials of are designed these preparation optimize schedules lymphodepletion dose dosing to and addition, ALLO-XXX In for in test to X trials. different Phase

trials for strategy host, their our call, this progress Later pipeline. lymphodepletion thereby the and ongoing our believe Raphael our will color validate leverage Phase additional broader We ALLO-XXX. trials our could X in on in provide

In we ALLO-XXXA introduce to next have testing. addition, generation into construct progress our made clinical

the you in eliminate As ALLO-XXX subtypes a to the domain may with was ALLO-XXXA created mechanism recall, previously to of ALLO-XXXA as receptor lymphoma different broadly in referred pivotal across using trial. intent ALLO-XXX.X and non-Hodgkin's of

to rapidly to clearance a are a the to X. study, have new ALLO-XXXA of dose be seek of of optimize explore number ALLO-XXXA abbreviated pivotal IND and in safety to and initiate We There patients limited potentially gained quarter ongoing including an Phase will the from this to and and ALLO-XXX program Phase year. trial of we our the efficacy ALLO-XXX ALPHA leveraged confirm second the of expecting learnings before work for submitted in X portion and advance

This to takes mouse that transformation.

generation develop to at us next will This Our to forefront is internal of external innovation and require field of always goal CAR research the from sources. and ALLO technologies, remain the in T therapy. thrive

technology that cytokines technology TurboCAR. Our of internal stimulation CAR novel research call T. mimics a We the developed within team ALLO selectively has effect this

fitness CAR cells, their TurboCAR potency, expansion enhancing persistence. the thereby have of to and the potential improve T ALLO overall

models increased stage with of with research in model Preclinical TurboCAR in More and to advancement to we refractory to shedding myeloma. leading and preclinical surface increase Secretase of levels of SpringWorks investigation evaluate and directed with Gamma the density an the in starting of prevent cell the BCMA with of the Nirogacestat BCMA In BCMA an combination surface is this entered to anti-tumor preclinical Gamma Therapeutics the has shown excited and collaboration Inhibitor, to reduce an multiple from clinical myeloma has ALLO-XXX in Nirogacestat development cells. vivo that BCMA that next recently we their enzyme in demonstrated TurboCAR. move Secretase approach of have BCMA. into are efficacy patients of cleavage cleavage relapsed been soluble

autologous addition, Secretase clinical suggests that efficacy the T may In BCMA-targeted CAR of therapy. augment data Gamma anti-tumor Inhibitor emerging

off this initiate combination trial long-term half second Therapeutics and We our Notch with start. of year. to In expect of the a strong ALLO-XXX in collaboration to the is Nirogacestat

enable Stem Pluripotent and chain, process team AlloCAR Success for consistency front starting from on together more the of product are highly Induced to based Cell cell derived working Our a more T streamlined the our or supply develop this could engineered potential research therapies. material. cells create production iPSC to greater

are this We you updated on field. our to in forward emerging progress keeping looking

I research will our and development who update on now call activities. turn to the you Raphael, will over

Raphael Amado

Thank you to call you, David and on the of morning good all today.

to ALLO-XXX quick I'd with on a start Non-Hodgkin program, Lymphoma. Relapsed/Refractory like for update lead our

our quarter. and from data a trial medical ALPHA is ALLO-XXX forward these in the we're for to earlier, ongoing Phase X second initial As sharing meeting David the noted Trial, looking

strategy. as on safety, to two are There an dose is things this consider. focus Phase lymphodepletion appropriately any the using Well X of escalation our trial trial also opportunity to optimize we're

academic dose drug autologous precedence First, research benefit much development lymphodepletion to Phase cell unlike lymphodepletion, and from and earlier X [indiscernible] regimens. trial a the point have the the of optimal little and the regarding starting that extensive regimen

can anti-CDXX possible produce differentiating The the one our tools our antibody we outcomes. second platform, of consideration best in the is to how harness most better ALLO-XXX,

dose on varying escalation that have trial additional doses three in enrollment completed of enrolling impact understand to three the recently the three allows move have schedule. and to us plus to cell better patients the or We ALLO-XXX cohorts

biomarkers and the data oncology team is potentially best translational patterns anti-tumor These to recovery persistence. activity correlation possible and parameters. believe scientific on the create historical T collecting include depletion outcome for important patients. to these is this We several expansion depth NKD [indiscernible] and evaluate approach necessary their duration the and including of AlloCAR to lymphodepletion essential T-Cell and Our understanding with

in clinical from the ALLO-XXX our ALLO-XXXA. the ALLO-XXX safety David’s regimen start trial. remarks momentum mentioning Trial intend and in the will we trial fully which and ALPHAX in includes done elucidate to ALPHA as Trial, gestation the started shares gene and a binding are advancing will rituximab being this strong The Phase of We execution treatment engineering construct epitope The as inform to into leveraging X the the UCARTXX a work off-switch. Trial being ALLO-XXXA optimal the ALPHA prior explore to same

to refer elected take from clinical in beginning parallel modified used on allows Allogene generation Pfizer relapsed/refractory which Acute lymphoma. in path lymphodepletion be strategy, The Lymphoblastic by a ALLO-XXX candidate Allogene which to on while to we non-hodgkin take designed now Early Leukemia. trials product, ALLO-XXXA. engineering to as acquired was clinical next This us on

While rituximab on that used. optimal early to lymphodepletion commercial we expect ALLO-XXX facilitate in commonly rituximab ALPHA data Trial initial the with clinical strategy, dosing setting identification and a is of recognized an we potential from the off-switch limit where

ALLO-XXXA to reason patient us allow the devoid Lymphoma rituximab recent this is For of rituximab those broader serve would which population patients Non-Hodgkin with including a exposure. off-switch,

will the with earlier, and quarter noted anticipate the output happy abbreviated by IND that the our we in the trial year. that Phase progress cleared have rapid of We David we're this ALLO-XXXA been preclinical of to of to development the has FDA. second X made As commence portion report

approximately expect ALLO-XXX X the elucidate move apply a to XX in we pivotal as potential patients and Trial toward optimize in Phase dose enroll we'll ALPHA the trial. We

strategy, accrue patients. multiple treat with regimen, for created anti-BCMA and we robust optimal to program, dosing platform also of This including will the of actively of In ALLO-XXX continues the myeloma. therapy clinical UNIVERSAL, Phase our treatment ALLO-XXX X ALLO-XXX components trial explore have relapsed/refractory which our second all at cyclophosphamide. a includes the lymphodepletion trial fludarabine and

for as duration ALLO-XXX. key cell endpoints of and safety, depths as assessing of anti-tumor the and activity success lymphodepletion, determinants will expansion We such tolerability, be

from on-track trial fourth XXXX. this to initial report quarter of are in We data the

also in the program ALLO-XXX will investigate with Secretase anti-BCMA Inhibitor, Nirogacestat. investigation Our SpringWorks on combination Gamma

to begin We route expect second the of this will the a and determine to best initiate year. in half trial combination

as look our The the third this of multiple pipeline. year lag earlier myeloma to broader our at strategy part

on function. candidate, have models AlloCAR activation enhances advancing XXXX. TurboCAR anti-BCMA increases an in IND T named which our as and in plan We phenotypes is for lead with development cell preclinical their ALLO-XXX ALLO-XXX clinical

to opportunity clinical with the by AlloCAR Lastly, T ALLO-XXX. have continue work officially candidate. we hematological program the our next our as progress to solid nominated preclinical tumors bridge and excited We're and ALLO-XXX, anti-CDXX malignancies

product cell and myeloid Our on acute malignancies focus renal leukemia, T-cell carcinoma. for this will be

expect by end of this the year. to submit IND We an

with and discovery Both providing I'm closing, forward In results in programs. the progressed very we clinical strong our of have to look year. later allogeneic this both excited and momentum clinical as planned

I’d turn financials. our the review Eric to to to like now call over

Eric Schmidt

Thank you, Rafael and morning. the

overview, In our financial quarter today call additional issued addition the to the I in press be brief today will which release our you read fourth on financial with earlier our results on year-end detail will the SEC. provide can and XX-K, filed in and

compensation to $XX.X the with investments cash of our third of quarter, which million, totaling XXXX. cash, expenses as continue and a December and We be $XXX.X position $X.X includes non-cash equivalents financial stock-based In in strong development million expense. were research XX, million

associated $XXX.X million, total research includes for $XX.X of the the of signing expense non-cash includes and year $XX expenses our development XXXX stock full Notch were expense. in the which For research million collaboration. expense development compensation The based with and million year

expenses General of quarter based expense. non-cash administrative $XX.X stock $X.X compensation million and included for XXXX, were million which the of fourth

the $XX.X which were of million, expenses For general compensation non-cash expense. and million based administrative $XX.X stock XXXX, year full includes

loss per million. $XX.X compensation Our $XX based quarter for of was the including stock $X.XX fourth non-cash or of XXXX net million expense share,

loss For of including or $XX.X non-cash per million net compensation the share, full stock $XXX.X XXXX, was million. year our based expense $X.XX

guidance now Turning to for XXXX. financial

Phase X ALLO-XXX our X of our is with progress the enrollment continue ALLO-XXXA By Trial our Phase complete initiate the in ALLO-XXX for will and and programs. this study Trial, to We in trials year X the heavily ALLO-XXX invest to clinical end Phase nirogacestat. goal combination

of the David's York manufacturing noted New build-out advance earlier As in facility. also comments, to we look our

million business result, development an $XXX we includes to between million a $XX this As any XXXX and impact compensation full exclude stock-based our $XX activities. million losses non-cash expense $XXX expect potential and to million, be year estimated net of from

now questions. open With that, will for we your the call

Operator

[Operator first Instructions] Frahm with and question from comes Company. Marc Our Cowen

Marc Frahm

taking going we're Thanks Hi. in update ALPHA to this Maybe Trial. questions. from my to quarter second get for the things the

mature maturity program. ultimately XXXA over the be able still of regimens do for You you that steps would make to to switch decision move a recognizing be there will can enough to data need to forward set you you this But going be into that laid that out? XXXA Phase and the is X cohorts? work-in on this and kind some have these pre-conditioning Or different kind of next of to progress it different need warrant more

David Chang

the is is question. David. And mean, this you're are important very goes the that Marc, I'll there question. that your different answering aspects asking into a I many take one. question certainly

those is generalizable lot the lymphodepletion you to we considerable the do the internally In the the that terms and a how spending things see by that, and have certainly have be couple both and ALLO-XXX a we'll concept is of should optimize to of as that in something amount that study of, about quarter. we’re lymphodepletion. is as a thinking time data in that bearing of one in that, those we reason we of effort present we findings know the And second been schedule ALPHA

is was with taking respect has realize And rituximab and that out remains expressed portion only in cost a primary thing transition making identical. question has off-switch, the the separate from protein. ALLO-XXXA the of antigen which of to changed that The one receptor ALLO-XXX the XXX to as

is as Phase can So the X we forward we we study with will directly and from as that ALLO-XXXA believe XXX learnings an our be prior and we statement. move have believe a done as said as be this reason relatively that change in abbreviated consider this we that the the minor study translatable that

Marc Frahm

go mean, as that Okay. get clarification mean of from abbreviate say but as does I does Phase exactly just what Can to When do up Trial, – abbreviated Like one X, selected start is, what have regimen ALPHA you you as you PK? reconfirm you you I can just single dose the ALPHA you exact to mean? low Do and can us that mean, do the some down? what, from a patients. dose in did mean I you go in you've

David Chang

have we I that, trial that in preclinical to learned years T over in confirm CAR that think in one I've is anything thing like that clinical studies. we do been the the I involved setting the

XXX is we when somewhat So that in point, we to escalation saw exactly reproduced can mean, talk study. about to be abbreviated real the approach whatever those intent in be I the XXXA and simplified will confirm

So for there'll you color present and a – wait we the has certainly more think I as that have to which with to it data be that. to

Marc Frahm

Okay. you. Thank

Operator

comes with Goldman Sachs. Richter next Salveen Our from question

Salveen Richter

Thanks, good morning.

that with the then XXX, of first program then pre-conditioning Are these here – NHL primarily see we're clinics, duration be with dosing steps programs the here? of dosing quarter. with as So so and about ASCO optimization other myeloma and you study timing about the other in into aspects data as presentation And thinking for AACR others, at efforts well where where you of program non-preconditioning any as further regimen secondly, SpringWorks the for regard among think multiple how to to kind leveraging look you second the of in could taking the as and you to dataset? and this thinking or going half play settings datasets

David Chang

the the our learning we other in first answer Salveen, going ALPHA of the question take the question study leveraging Okay. to programs. are second will regarding Raphael I how and I'm part to ask the from

exactly around question. do presented, get that The the and question when we data

the will or it EHA are is be the for close to at point, to very think meeting. fair this and presentation ASCO that say our I We target quarter either second

Raphael Amado

BCMA address question. Rafael and I'm this Salveen, going is your to

on the XXX use that that program. XXX learning So mimicked BCMA from the in program. the changes that lymphodepletion question XXX there's introducing are Any in can customer and no

But are sale in at and PK/PD value be rituximab testing introduced and such XXX and were fludarabine to of and cyclophosphamide other expansion You may which by of the ING well that as are will we of as, to obviously things other study designed beginning lymphodepletion that itself. that study, of parameters. the interactions, recall XXX there ascertain [indiscernible] changes higher outset kinetic in some doses that ING recovery, in the

it in XXX think and will we the that into making data. the will learnings see translate expect We as I decision accelerate from help therefore us XXX

Salveen Richter

you. Thank

Operator

comes Our with Amin Jefferies. next Biren from question

Biren Amin

Yes. Maybe taking since you're could XXXA. likely the Thanks requiring not for change switch? XXXA and XXX Hi, How going increase guys. to with my with XXX, I yields your questions. efficiency if do is start transduction versus your given

David Chang

and I into very viral Biren, going do we and we the mean all are process well you is from been that technical straight when development you And team have we expectations. titer are where the I these and Yes, exceeding less that tell getting really worked as can all very yield to manufacturing strong the changes have that's you – a manufacturing make the a out our or question. team construct issues other of when it, change. more change things

a don't being this So major see I really issue.

Biren Amin

there's you're just Okay. to ask XXX when you I want going the data in where And present guess whether second quarter, the then I undetectable. see a cells risk to

So the where data seeing dash where XXXX they assay, undetectable. when presented were you’re cells using competitors early

issue of risk what's seeing XXX? in arise the similar So a

David Chang

member, we our of mean, kinetics into But are which vector steps least, we have is just not to and number data me studies. this working ready cellular you biomarker quite tell about that the the presentation, to reliable a you and personally it. portion terms we I of talk have of Well, in CAR-T data let are get at topic took for can some make in sure years I been of our we necessary that going

components stop But member just translational there CAR-T of too without research. of me what let much exactly the about vector will be present. is revealing So important one we the

Biren Amin

I question if a ask could maybe then And on Okay. BCMA.

with how QX when I you guess, So start few about be to ASH are responses, really dosing guess, And you for Fred and XXX? data GSI from guess, I the X, GSI Hodge good we and data CAR program the observe GSI also patients. the you planning neurotoxic ago, the – Phase after and when will the David six do thinking and on presented saw to I do it a months XX expect also the

profile So anticipate safety that change of the the with do you use GSI? would

David Chang

very pretty going into are feel answer intensely I'm question. to quick Rafael Rafael? been baseline this looking has there Great that ask I area mean, study. to I the question. on embark well and particular we

Raphael Amado

Yes. Thanks, David.

in this plan second the of we study start the half So to year.

collaboration molecule these great It brain patients. a our We're leashes excited We PK/PD SpringWorks. profile. is treated have barrier them. I this penetrate have with being We and with the the over not good, think neurotoxicity. about pretty interactions really observed really so of XXX initial doesn't blood

the which safety So trial. wise, profile very understood when useful is combination it's a well pretty you're doing

you which a regards obviously helps as registration co-development. they've And the to path, with know, potential got

lot combination, DCMA and So to which it into result our the this right know expression forward will a both be increasing is But hopefully applying data and to testing far better pretty so combination and to the the translate patients. we understand outcomes strong dosing we will product. about do superiority think probably of we to start look try whether this we pre-clinical time would in combination, actually the lymphodepletion time by for

David Chang

great. Okay, you. Thank

Operator

comes for question from JP Kasimov next Cory Our Morgan.

Unidentified Analyst

for Hey, Thanks for guys. Cory. is questions. This on my taking Matthew

range narrow wondering the wondering XXXA the based Basically question, dose discuss initiation. to in study. time lymphodepletion I'm of just trial abbreviated terms in first enough mature you dose on to you if my be XXXA a for whether resolve for expect in of levels data lymphodepletion expect at abbreviated the more to you hand levels can what ALLO-XXX So have of the

David Chang

David. this is Matt, So,

it's the XXXA in counts learnings that findings. mean, I Let is cell be elaborating saying in the we dealing really given, and lymphocyte because other me XXX mean generalizable the XXX I our programs. quite programs this question. will including are view before a the have the lymphodepletion, also host been with take that we from in definitely

be any question, learnings lymphodepletion ultimate in to the cohorts. remarks, And recruiting regimen and escalation will have patients dose are stat. prepared have the completed we your we So said of actively fine ALLO-XXX into a as we

will projection that leveraged So is move definitely we some ALLO-XXX our in we be that with study. forward have and how will current inflammation

Unidentified Analyst

Great, thanks. And CD-XX X then comparing ALPHA the keep what guess sets autologous I Trial, the when initial mind the set Phase for space? in we data data to from should

David Chang

you repeat Sorry. the Can question?

Unidentified Analyst

the ALPHA this Just data in mind sets X wondering comparing for initial set, CAR what T data should we initial the when autologous other from Phase CD-XX keep space? to

David Chang

cautious little cell be you and lymphodepletion. we be at to with Certainly when being we point better But the too patients that therapy of in – also just that reported what are setting, trying get realize data. that the have very We’re in Allogene mean, fact dealing with been XXX if I the has we bit a one. about are a you're is outcome bearing talking a relatively asking autologous. about to number present important well to that the will not Phase question than we'll of much terms as what as the the the not presented safety is similar, X small

is there inflammation. some So of different sets

the So data. just wait till present we

Unidentified Analyst

my taking Great. Thanks for question.

Operator

Van Buren Tyler comes question next from Piper Sandler. with Our

Tyler Van Buren

DLBCL enrolling expect just split with approximately think Hey congrats confirm the of the the next rough ALPHA patients guys. respect possible data patients mentioned to between progress. what to in quarter. follicular we in to on With should it and you're final you morning, I respect XXX, the regimen. number lymphodepletion Good lymphoma And is? the Is update

you XX us where can a of of XX in the to big range? terms sense is give XXX So

David Chang

into be presented. to much too going we're what of details So is the

going So we let I'm the we of say. your we escalations. deal prepared statement, give dose to to nine that patients what question. patient those to try a limit completed number should color and certainly minimum dose gain the into to But some in escalation I said alone patients I to mean going are and that try on just me get nine

nature duration but you let is about hopefully present, me when emphasize the asked color what's and to cut. that may lot So of evolving. will the be gets data may patient what happens, there time a some of that all get the when And presentation very gives enrolled. we the dependent about that of also data that how you be dynamic But of presenting a on lot data the are to the sort going is see the data available we

Tyler Van Buren

helpful. That's cytokine be more how can maybe other about say respect if go to the plan to guys and Okay. into may and for of you to then approaches some you compares with chose well you cytokines And using it TurboCAR, the to guys anything it or you why what non-Hodgkin's with using relatively myeloma start known

David Chang

Yes.

else driven – what have so I've called Signal is many seen to enhance and For far cytokines and competitive by extra TurboCAR so different but is, anything a reasons, far what we're not T the than that seen have that the X, going better before. Cells engineered to talk I'm about the we which in to provide seeing seen cytokine over we the years ways

this about excited quite TurboCAR. are we So

Tyler Van Buren

That's very exciting. you. Thank

Operator

Our Mark with from Oppenheimer. comes Breidenbach next question

Mark Breidenbach

for depth questions. morning see that different realistic multiple wondering, it the just to and it's good the is indications, probable on do thanks lymphodepletion and more Hey, that taking of disease? think depending different ALL, guys will I'm sort the you myeloma expect universal David, likely duration across requirements be or lymphodepletion, NHL, requirements we'd

David Chang

in clinical of about to study. And or am I indication-by-indication mean, although X I question. we are surprised do that's I Phase knew the wish answer, always doing differences. years have the there the patients-to-patients Great trials, I exactly what

the optimize lymphodepletion will the as indications. the a in information understand it, thinking simplify use used to way and exploration So good we the framework that have as we very other six lymphodepletion to about be that ALLO-XXX, we, and

other are how effective in lymphodepletion from that's exploration that approach we learnings be the programs. will other And ALLO-XXX I think really indications. So their and leveraging very in simplifying

Mark Breidenbach

to a you've wondering lot trial, in so, rituximab recent failures ALPHA seeing you're to follow-up a rate at if expect a quick with due faster if regard to than of ALPHAX ALPHA? what enrollment able in proceed just the to achieve you I'm and would And Okay. exposure, screening been

Raphael Amado

Raphael, Mark, the Yes. question. I'll this answer is

is we've with with observation, that are brisk. pooling but accrual committed very very a based very has been exposure, at spite and as think that we're I to that, to of great investigators we that be been planned fortunate have want study. perceptive work our and but we on And customer where exactly actually been very in

that And would it'll mentioned. the allow be and clearly, allowing elucidate go able with for all that us but to move an ALLO-XXXA because actually find study it's these fantastic Now investigators us we quicker. with think faster, will ALLO-XXXA anticipate reasons parameters are you it's easier patients to ALLO-XXX hopefully accrue that to I for to it

I yes, to observation, you're actually but it's right in ability our not So really your limiting on mean, involve ALLO-XXX.

Mark Breidenbach

questions. for the Thanks Terrific. taking Okay.

Operator

comes Our Newman John next with Canaccord. question from

John Newman

Hi Good Thanks my guys. morning. question. taking for

question, we study, a see Just know look the much redosing the David, data chance don't get had we've there might about I you that get the details general in to to data, ALLO-XXX the of second is quarter? a when want but into too at

David Chang

see to see the that you'll exactly many think one going don't definitely data. into you not we patients, protocol A how great of some certainly but question, the data we it's I'm changes introduced redosing will say, some and

John Newman

and I using, co-stim and product but about this be different, I'm we in with worry and about? I X-XBB CDXX cells? development back, efficacy curious debate little a very autologous host Is graft is thinking longer setting the Because then whether we bit here, Novartis certain out about thinking turned in there that the that dealing was detection about same. And that that question, big the persistence almost about efficacy one was had know about was a the Kite great. just this better a how CAR maybe when different but this with and there because remember very the we're to broader. was both that? was threshold can going Novartis versus should you product versus to how which product is CDXX CAR of be that should follow-up you're a little with sure result here just ultimately have know Okay, the persistence bit allogeneic, we well Kite thinking T a you talk their is

David Chang

impact on that be durability that very killing And the cells going that how maintained existing in asking, which question question follow-up that's answer. John, different this we have coming to the non-Hodgkin's answer the the I'm are the somewhat will lymphoma, response. of if less, whatever has high, tumor lymphoma. non-Hodgkin's of a in more or which to that of a likelihood the response about Yes. month setting. is three, really it are really way, a that the you complicated In from is in in the response is you great means sort at initial longer very experience self-persistence thinking

UCARTXX is bit months, longer. data, we'll we detail of you And that own data, study. the study. to sometimes a our if self in cell level you look at containing of findings secondly, and that present probably And little we if about something constructs, the when talking self-resistance close on the two more achieved be data, some UCARTXX the able especially CDXX oncologists domain And that T ALLO-XXX three to are to with was CAR in persistence we see mostly persistence, expansion look

John Newman

Thank Great. you.

Operator

comes JMP Securities. Our next from question Reni with Benjamin

Reni Benjamin

and questions Thanks both, allogeneic space space cells regarding do is congrats how moving the progress. on shaping I where a donor evolves just IPSE of morning. you Do there's kind the that, something that out guess you taking this the Is think and for you're this over, good take forward? and see healthy for this ultimately IPSE’s? how question your IPSE picture broader seeing evolve. Hi, programs

Raphael Amado

give is is mean, but asking I'll I Raphael, unanswered. are this you what try, a still it Well,

I extremely a characterized think, the is obviously theory product have and field a that is the us the allow would IPSE will field one, it homogeneous we or inexhaustible for exciting, transform which field. in well allows to

being to same T-cell, ligands is I and [indiscernible] still the terms differentiation worked of be penetrate and they both have I mean, come will that's think out. enlarge of T-Cells after that re-engineered the will molecules, persistence, they the receptors in still differentiation capacity, tumor. et cytokines, to cetera, function, in finding similar T characteristics maintain cell IPSE

we what in these we're promising need I will happens case that things, starting see pretty think all and is it. excited space the to and be to we're see evaluated, of but IPFC for about end differentiation

And Notch, pretty collaboration hard really is also that good a with know, as – you we're working that which start.

And have trials and maybe focus so we of And are the our for will this using meaningfully bleeding, the gene parallel, we the terms think in this – but be to et make in normal I as working to the dosing, the donors and in moment, as best terms bring interesting well. are how ones compared such future, will have with the forward like that see leading how evolves. we we future technology will process, clinic, is become what we we of it clinical in that parameters donor and that issues expect allogenic autologous therapy recruiting donors, healthy ascertaining persistent, plan been think to and At to will evolve the cetera. I

to think great I watching be the of space more make available feel it's of to patients, that, setting. opportunities fantastic the that so So the a which sort that least, easier, it's I and advancing it's technologies at it in case would many this IPSE there's in are matter

Reni Benjamin

there – donor And I else donors to want? being things is down is stage going there's regarding of and parameters lines lymphodepletion along terms just donor everything and much healthy of later you Or in the do and a types followup, of cells donors, the those you anchored change? that's of lot know pretty you're still work work on focusing that done as largely cells lot into a a a regimens ideal feel and

David Chang

improve Reni, sort runs, But are as that having continuing and bit on we topic we feel selection we we'll is certainly of investigate to I successes mean, less let me that that based we that a of manufacturing, a of such an became take have super interesting the a our question. think are mean, But I on super we data I all how more knowledge whether based the build will these how manufacturing understand, see is out the to applied there continuously process, there, that's program be individuals that point donors cannot we improvement, into issue. improve ultimately, an little donor. that, a it. donor manufacturing the manufacturing with do more learnings we will to really translate as

Reni Benjamin

Got I are just evaluating? guess, final it. that you're one redosing for question, what And going back to us the talk just the just redosing you – protocols me, can through, one

David Chang

question. So that take I'll

the redosing. the amendment for announced that last we that's So call, at a lot

could then lymphodepletion are very to there redosing recovered, to previous some In have benefited out past, the where course allogenic seen the have would conditioned which have addition [indiscernible] the antibodies to the meet which convert autologous patients, in protocols have need that we be using that we simple are in parameters lymphodepletion, dosing to eligible close develop they they cells enrolling that for if to it they're longer patients have some against the disease, they are are being of the or we cars redosed. that These into again. eventually donor, and than the patients be setting. fairly patients stable in patient time rule probably that but are redosing is has conditions, and the allow few If is the for given

flexibility patients and patients, to do to think, they how have we seeing off-therapeutic see a very we antibody, us with behave but objective informative of amendments. are therapy, We main gives change likewise, what to I having maximum which So remains be understand prior will look-forward the what see after also of that our flexibilities. lymphodepletion the happens which it CAR progressed lot those think utilize behave to to we the the some to patients, those some it those have how in on made would – optimal those and the of benefit,

that of platelets something for side, They granular maintain [indiscernible] some STEM cells are and allow allows lymphodepletion for to engraftment. recovery remain,

our the focus really is that I the regimen. what is So optimal length of depletion think is now

Reni Benjamin

on Thank progress. And congrats Great. you. the

Operator

Our next comes Blair. [indiscernible] question from William with

Unidentified Analyst

on for Raj. Hi taking questions David, for Thanks the Sammy congrats my on progress. and

follow-up. the still a are programs in then you same of dose the eventually dose you will at know you couple upon patients giving in I early, ALLO-XXX curious, have parallel? are guys replace me, it's two a So redosing advance was the thinking I or And then housekeeping ALLO-XXX to you regards redosing? are are And higher redosing, I a quick ones those program but will quick of thinking the that for kind or TurboCAR

David Chang

great this really point, question. in ALLO-XXX is different ultimately, take in Sammy, go that, Because of patient Chang on we field next this just indication a believe of we make certainly a and accommodate Yes. early one, the lot approaches will that based I have generation different ALLO-XXX, at too and that one outcome than can we the multiple-myeloma will the opportunities but decision generation examine a to and it? more is this first on question and not how whether or David simultaneous I'll leads to But it's a around approaches and we different terms different answer how can with provides way.

reason we one of up and the our BCMA that the advancing multiple-myeloma. are So really towards that's approach

Unidentified Analyst

Great.

Operator

call question any to to over session, conference Thank like answer for turn comments. back you. I’d additional This the concludes the and management

David Chang

we you for you us call on exciting disconnect. Well, support be continued joining and Operator, this today now for thank therapy. of allogenic an will know may what you're year Allogene, cell

Operator

This gentlemen, the participating Thank thank and may conference. and all you today's you. Ladies log-off program, for you does in conclude disconnect.

Allogene Therapeutics (ALLO) 27 Feb 202019 Q4 Earnings call transcript